Syndax reports updated Phase Ib/II data for entinostat combo

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) reported updated response data from the open-label, U.S. Phase Ib/II ENCORE 601 (KEYNOTE 142) trial of entinostat (SNDX-275) plus PD-1 inhibitor Keytruda pembrolizumab to treat melanoma, non-small cell lung cancer (NSCLC) and microsatellite stable colorectal cancer. The

Read the full 416 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE